New Treatments & Clinical Trials for Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) are a group of bone marrow disorders where abnormal cells crowd out healthy blood cells, causing anemia, infections, and bleeding. About one-third of MDS cases eventually progress to acute myeloid leukemia, making early and effective treatment critical.

What's actually going on in research

Luspatercept has transformed anemia management in lower-risk MDS by promoting red cell maturation, and imetelstat — a telomerase inhibitor — has shown meaningful responses in patients who have failed erythropoietin therapy. For higher-risk MDS, hypomethylating agents remain backbone therapy, but venetoclax combinations and new agents targeting splicing mutations (SF3B1, SRSF2) are being tested. Stem cell transplant remains the only potentially curative approach for high-risk disease, and trials are expanding access and testing post-transplant maintenance.

What to know before you search

Eligibility requires confirmed MDS diagnosis with specific IPSS-R risk score, transfusion dependence status, splicing or other mutations, and prior treatment with hypomethylating agents.

What types of trials are currently open

• Treatment trials — Testing new drugs for lower-risk MDS to reduce transfusion dependence and delay progression.
• Higher-risk MDS trials — Testing hypomethylating agent combinations and new targeted drugs for high-risk and secondary MDS.
• Transplant trials — Evaluating conditioning regimens and post-transplant therapy to prevent relapse.
• Gene therapy trials — Testing gene editing and correction strategies for specific MDS-driver mutations.
• Supportive care trials — Comparing transfusion thresholds, iron chelation, and infection prevention strategies.